pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

immunitas-therapeutics PRESS RELEASE ARCHIVE

Sep 21, 2022

Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies

Aug 18, 2021

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

Feb 17, 2021

Immunitas Therapeutics Announces Cell Publication of Tumor Single Cell Analysis Identifying CD161 as a Therapeutic T and NK Cell Target in Immuno-Oncology

Dec 18, 2019

Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics

Nov 21, 2019

Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform

Google Analytics Alternative